

Patient ID SA00168950	Patient Name TESTING, BRMLH ATLAS	Birth Date 1994-06-05	Sex F	Age 30
Order Number SA00168950	Client Order Number SA00168950	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 14 Jun 2024 10:00		

MLH1 Hypermethylation/BRAF Mutation

MLH1 Hypermethylation/BRAF Mutation

Result Summary

NEGATIVE MLH1 METHYLATION/NO BRAF MUTATION IDENTIFIED

Result

Provided diagnosis: colorectal adenocarcinoma

Methylation status: Negative for MLH1 promoter hypermethylation

BRAF status: Wild-type

Interpretation

These results do not provide evidence for the somatic/epigenetic inactivation of MLH1. Together with the loss of MLH1 protein expression in this patient's tumor, these results suggest the presence of a germline mutation.

Germline testing of the MLH1 gene (CGPH / Custom Gene Panel, Hereditary) on an additional blood sample should be considered, if not already performed. Please contact the Genomics Laboratory 1-800-533-1710 for more information regarding germline testing for MLH1.

A genetic consultation may be of benefit.

Specimen

Tissue, Tumor

Tissue ID

1234

Method

Microscopic examination was performed by a pathologist only to identify areas of tumor for enrichment by macrodissection. A PCR based assay was used to test tumor DNA for the presence of MLH1 promoter hypermethylation and tumor DNA for the presence of the V600E (Val600Glu) mutation in the BRAF gene.

Disclaimer

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Rare polymorphisms exist that could lead to false-negative or false-positive results.

A negative result does not rule out the presence of the V600E mutation that may be present but below the limits of detection for this assay (approximately 10%).

Released By

ANDE RUMILLA

BRAF Analysis

Performed

MLH1 Hypermethylation Analysis

Performed

Received: 14 Jun 2024 13:23

Reported: 16 Jun 2024 15:22

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	Nikola Baumann Ph.D.	24D0404292